BTIG raised the firm’s price target on iRhythm (IRTC) to $190 from $165 and keeps a Buy rating on the shares after its Q2 results and revenue guidance raise. The company’s Q2 sales strength was driven most meaningfully by demand in the core business, with increased Zio AT market penetration and revenue from new innovative channel partners contributing equally to the rest of the beat, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm price target raised to $180 from $160 at Baird
- iRhythm Technologies: Strong Performance and Growth Potential Justify Buy Rating
- iRhythm price target raised to $170 from $139 at Canaccord
- iRhythm price target raised to $190 from $145 at JPMorgan
- Irhythm Technologies: Strong Performance and Growth Potential Drive Buy Rating